Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of GPN01020 capsules for migraine prevention
CTR20263728Phase 2Active
- Sponsor
- Grand Pharmaceutical Group
- Start
- Sep 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in migraine comparing GPN01020 capsule with Placebo comparator (2 arms). Primary endpoint: Mean change from baseline in monthly migraine days. Started Sep 2026; status: active.
02
Drugs
GPN01020
03
Conditions
migraine
Beyond the preview
Go deeper on CTR20263728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263728.